Establishment of appropriate termination method of dexmedetomidine in pediatric patients

Establishment of appropriate termination method of dexmedetomidine in pediatric patients - Establishment of appropriate termination method of dexmedetomidine in pediatric patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020387

Enrollment

Registered

2016-01-01

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All pediatric patients aged 15 years and under given dexmedetomidine in their treatment corse

Interventions

Change termination process of dexmedetomidine administration from sudden termination to gradual weaning.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All pediatric patients who are scheduled to receive intravenous administration of dexmedetomidine either in Intensive Care Unite (ICU), Operation Room (OR), or Ward with written consent by their guardians.

Exclusion criteria

Exclusion criteria: In case participation to the research was declined or withdrawn by guardians.

Design outcomes

Primary

Measure	Time frame
Prevalence of dexmedetomidine withdrawal syndrome within 6 hours after discontinuation of dexmedetomidine based on abnormal vital signs and sedation scores	—

Countries

Japan

Contacts

Public ContactShun Yanai

Toho University Omori Medical Center Department of Pediatrics

shun.yanai.md@gmail.com03-3762-4151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026